Emcure Pharma Q4 Results: Stock slips from 52-week high despite revenue, margin growth

Emcure Pharmaceuticals Ltd reported a steady set of Q4 FY26 earnings on May 5, with profit growth led by healthy international business momentum and margin expansion.

Net profit for the quarter rose 29% year-on-year to ₹243 crore from ₹189 crore. Revenue increased 16.7% to ₹2,469.7 crore compared to ₹2,116.2 crore in the year-ago period, reflecting healthy traction across key markets. EBITDA grew 19.2% to ₹479.5 crore, while margins improved marginally to 19.4% from 19% a year earlier.

The company’s international business remained the key growth driver, with sales rising 25.7% YoY to ₹1,493 crore, supported by base business ramp-up and new product launches.

Domestic sales came in at ₹977 crore, up 5.2% YoY, impacted by softer performance in the Zuventus portfolio and organisational restructuring.

The stock reacted negatively, falling over 5% in intraday trade on the NSE after hitting a 52-week high of ₹1,830 earlier in the session.

The board recommended a final dividend of ₹3.60 per share for FY26, subject to shareholder approval. It also approved the re-appointment of Dr Mukund Gurjar as Whole-time Director for one year from August 2026, and Satish Mehta as Managing Director for five years from April 2027.

Also Read: Alkyl Amines Q4 Results: Profit, revenue largely flat; dividend declared

Commenting on performance, management highlighted strong execution in the first year of its five-year strategic plan, with international markets driving growth and continued focus on complex injectables and biosimilars expected to support long-term expansion.